unknown
Stage
About
AllRock Bio is a clinical-stage biotechnology company developing a small-molecule pan-ROCK inhibitor to treat cardiopulmonary and fibrotic diseases, including pulmonary hypertension and interstitial lung disease. The company focuses on advancing therapies from development through commercialization for pulmonary and fibrotic indications.
Explore AllRock Bio's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.